Related Experiment Video

Updated: Mar 11, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.6K

FGD1 guanine nucleotide exchange factor drives secondary resistance to BRAF inhibition in melanoma

Guy Namir1,2, Mounib Elchebly1, Andreas I Papadakis1

  • 1Lady Davis Institute.

Melanoma Research
|March 9, 2026
PubMed

Insights

FGD1 gene expression impacts melanoma cell growth and resistance to BRAF inhibitors. Targeting FGD1 may offer new therapeutic strategies for melanoma patients with BRAF mutations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • FGD1 (faciogenital dysplasia 1) is an X-linked gene.
  • It functions as a guanine nucleotide exchange factor for Cdc42, influencing cell processes.
  • High FGD1 expression correlates with poor survival in melanoma, particularly in BRAF-mutated cases.

Purpose of the Study:

  • To investigate the role of FGD1 in melanoma progression.
  • To understand FGD1's involvement in acquired resistance to BRAF inhibitors.
  • To explore FGD1 as a potential therapeutic target in melanoma.

Main Methods:

  • Utilized melanoma cell lines with BRAF V600E mutations.
  • Performed FGD1 knockdown experiments.
  • Analyzed cell proliferation, resistance to BRAF inhibition, and expression of resistance markers (EGFR, phospho-PAK).

Main Results:

  • FGD1 knockdown reduced melanoma cell proliferation and induced resistance to BRAF inhibitors.
  • Knockdown also increased sensitivity to p21-activated kinase (PAK) inhibitors.
  • Resistant cells upregulated FGD1, EGFR, and phospho-PAK, indicating an adaptive resistance phenotype.
  • Prolonged BRAF inhibitor exposure led to reduced FGD1 levels.

Conclusions:

  • FGD1 plays a critical role in melanoma progression and the development of secondary resistance to BRAF inhibitors.
  • The FGD1-mediated signaling pathway represents a promising therapeutic target for melanoma treatment.
  • Understanding FGD1's role is crucial for overcoming treatment resistance in BRAF-mutated melanoma.
Keywords:
epidermal growth factor receptormelanomap21-activated kinasetherapy-resistancevemurafenib

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

14.2K

Related Concept Videos

Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.6K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60